HMMR and prostate carcinoma: Indeed, inhibition of RHAMM using a mimetic peptide, P15-1, coincided with decreased myofibroblast differentiation and expression of mesenchymal markers such as vimentin and N-cadherin, resulting in decreased migration of fibroblast and prostate cancer cells (108).